Literature DB >> 24430095

Pacing-associated left ventricular dysfunction? Think reprogramming first!

John Gierula1, Haqeel A Jamil, Rowenna Byrom, Eleanor R Joy, Richard M Cubbon, Mark T Kearney, Klaus K Witte.   

Abstract

OBJECTIVE: Heart failure and left ventricular systolic dysfunction (LVSD) are common in patients with permanent pacemakers, but whether right ventricular (RV) pacing is contributory or merely a bystander in patients with more severe cardiac disease is controversial. The aim of the present study was to determine whether reprogramming of existing pacemakers to reduce RV pacing is safe and leads to improvements in cardiac function.
METHODS: This was a prospective service evaluation of the effects of optimising pacemaker programming to avoid RV pacing in 66 consecutive attendees of a teaching hospital pacemaker clinic without complete heart block. The main outcome measures were left ventricular ejection fraction (LVEF), N-terminal pro-B-type natriuretic peptide (NT-pro-BNP) levels, quality of life and cardiopulmonary exercise testing at baseline and after 6 months.
RESULTS: At 6 months, the protocol reduced absolute RV pacing by a mean of 49% (95% CI 41% to 57%) (p<0.0001 from baseline) and resulted in a mean absolute improvement in LVEF of 6% (4% to 8%) (p<0.0001 from baseline) but no reduction in exercise capacity, NT-pro-BNP or quality of life. There was a relationship between the magnitude of change in EF and the reduction in RV pacing (p=0.04) and changes in NT-pro-BNP seemed to relate to change in RV pacing (p=0.07).
CONCLUSIONS: Programming standard pacemakers to avoid RV pacing is safe, does not adversely affect patients' symptoms or quality of life and is associated with improved LV function, related to the reductions in RV pacing percentage.

Entities:  

Keywords:  heart failure; left ventricular dysfunction; pacemaker

Mesh:

Year:  2014        PMID: 24430095     DOI: 10.1136/heartjnl-2013-304905

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  4 in total

1.  Optimising pacemaker therapy and medical therapy in pacemaker patients for heart failure: protocol for the OPT-PACE randomised controlled trial.

Authors:  Maria F Paton; John Gierula; Haqeel A Jamil; Judith E Lowry; Rowena Byrom; Richard G Gillott; Hemant Chumun; Richard M Cubbon; David A Cairns; Deborah D Stocken; Mark T Kearney; Klaus K Witte
Journal:  BMJ Open       Date:  2019-07-17       Impact factor: 2.692

2.  Detrimental Immediate- and Medium-Term Clinical Effects of Right Ventricular Pacing in Patients With Myocardial Fibrosis.

Authors:  Christopher E D Saunderson; Maria F Paton; Louise A E Brown; John Gierula; Pei G Chew; Arka Das; Anshuman Sengupta; Thomas P Craven; Amrit Chowdhary; Aaron Koshy; Hazel White; Eylem Levelt; Erica Dall'Armellina; Pankaj Garg; Klaus K Witte; John P Greenwood; Sven Plein; Peter P Swoboda
Journal:  Circ Cardiovasc Imaging       Date:  2021-05-18       Impact factor: 7.792

3.  Personalised reprogramming to prevent progressive pacemaker-related left ventricular dysfunction: A phase II randomised, controlled clinical trial.

Authors:  Maria F Paton; John Gierula; Judith E Lowry; David A Cairns; Kieran Bose Rosling; Charlotte A Cole; Melanie McGinlay; Sam Straw; Rowena Byrom; Richard M Cubbon; Mark T Kearney; Klaus K Witte
Journal:  PLoS One       Date:  2021-12-13       Impact factor: 3.240

Review 4.  Devices in heart failure; diagnosis, detection and disease modification.

Authors:  John Gierula; Mark T Kearney; Klaus K Witte
Journal:  Br Med Bull       Date:  2018-03-01       Impact factor: 4.291

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.